PER-037-14已完成未知
PHASE 3B/4 RANDOMIZED SAFETY ENDPOINT STUDY OF 2 DOSES OF TOFACITINIB IN COMPARISON TO A TUMOR NECROSIS FACTOR (TNF) INHIBITOR IN SUBJECTS WITH RHEUMATOID ARTHRITIS
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- PFIZER S.A.,
- 入组人数
- 190
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 50 至 99（—）
入选标准
- •1.Moderate to severe rheumatoid arthritis
- •2.Taking methotrexate without adequate control of symptoms
- •3.Have at least one cardiovascular risk factor (eg, current smoker, high blood pressure, high cholesterol levels, diabetes mellitus, history of heart attack, family history of coronary heart disease, extra-articular RA disease)
排除标准
- •1.Current or recent infection
- •2.Clinically significant laboratory abnormalities
- •3.Pregnancy
研究者
相似试验
进行中（未招募）
1 期
A clinical study to evaluate the safety of two different doses of Tofacitinib for the treatment of rheumatoid arthritis.MedDRA version: 19.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2013-003177-99-SEPfizer Inc. 235 East 42nd Street, New York, 100174,000
进行中（未招募）
1 期
A clinical study to evaluate the safety of two different doses of Tofacitinib for the treatment of rheumatoid arthritis.MedDRA version: 19.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2013-003177-99-ATPfizer Inc. 235 East 42nd Street, New York, 100174,000
进行中（未招募）
1 期
A clinical study to evaluate the safety of two different doses of Tofacitinib for the treatment of rheumatoid arthritis.MedDRA version: 21.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2013-003177-99-FIPfizer Inc., 235 East 42nd Street, New York, 100174,000
进行中（未招募）
1 期
A clinical study to evaluate the safety of two different doses of Tofacitinib for the treatment of rheumatoid arthritis.MedDRA version: 20.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2013-003177-99-CZPfizer Inc.4,000
进行中（未招募）
1 期
A clinical study to evaluate the safety of two different doses of Tofacitinib for the treatment of rheumatoid arthritis.MedDRA version: 20.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2013-003177-99-SKPfizer Inc.4,000